836619-77-3

Basic information

• Product Name: N-Boc-3-bromo-4-fluoroaniline
• Synonyms: N-Boc-3-bromo-4-fluoroaniline;(3-Bromo-4-fluoro-phenyl)-carbamic acid tert-butyl ester
• CAS NO: 836619-77-3
• Molecular Formula: C₁₁H₁₃BrFNO₂
• Molecular Weight: 290
• Mol File: 836619-77-3.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: N-Boc-3-bromo-4-fluoroaniline(CAS DataBase Reference)
• NIST Chemistry Reference: N-Boc-3-bromo-4-fluoroaniline(836619-77-3)
• EPA Substance Registry System: N-Boc-3-bromo-4-fluoroaniline(836619-77-3)

Safety Data

• Hazardous Substances Data: 836619-77-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-Boc-3-bromo-4-fluoroaniline is used as a building block in organic synthesis for the development of various drugs and drug intermediates. Its halogenated aromatic structure and Boc protecting group contribute to the creation of complex organic molecules, enhancing the compound's utility in medicinal chemistry.
Used in Organic Synthesis:
In the field of organic synthesis, N-Boc-3-bromo-4-fluoroaniline serves as a versatile intermediate. Its reactivity and the ability to remove the Boc protecting group under mild conditions make it an essential component in the synthesis of a wide range of organic compounds, including those with potential applications in various industries beyond pharmaceuticals.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1257294-51-1 6-bromo-5-fluoro-pyridin-2-ylamine 
• 656-64-4 3-bromo-4-fluoroaniline 
• 1007-16-5 3-bromo-4-fluorobenzoic acid 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 656-64-4 3-bromo-4-fluoroaniline 
• 1269815-47-5 (3-bromo-4-fluorophenyl)-(tetrahydropyran-4-ylmethyl)carbamic acid tert-butyl ester 
• 902121-19-1 tert-butyl (3-anilino-4-fluorophenyl)carbamate 

Relevant articles and documents

Mild deprotection of the: N-tert -butyloxycarbonyl (N -Boc) group using oxalyl chloride

We report a mild method for the selective deprotection of the N-Boc group from a structurally diverse set of compounds, encompassing aliphatic, aromatic, and heterocyclic substrates by using oxalyl chloride in methanol. The reactions take place under room temperature conditions for 1-4 h with yields up to 90percent. This mild procedure was applied to a hybrid, medicinally active compound FC1, which is a novel dual inhibitor of IDO1 and DNA Pol gamma. A broader mechanism involving the electrophilic character of oxalyl chloride is postulated for this deprotection strategy. This journal is

PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS

Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa)

PHENYL-HETEROARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I, and pharmaceutical compositions comprising such compounds

HETEROARYL COMPOUNDS AS KINASE INHIBITORS

The present invention provides a compound of Formula (I): and pharmaceutically acceptable salts thereof. Also provided is a method of using a compound of Formula I for treating a disease or condition mediated by a CDK inhibitor

QUINOLONE DERIVATIVE OR SALT THEREOF

A platelet aggregation inhibitor comprising a quinolone derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and a novel quinolone derivative or a pharmaceutically acceptable salt thereof useful as a platelet aggregation inhibitor.